Reversible and adaptive resistance to BRAF(V600E) inhibition in melanoma
Open accessThe DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Abstract
Treatment of BRAF(V600E) mutant melanoma by small molecule drugs that target the BRAF or MEK kinases can be effective, but resistance develops invariably. In contrast, colon cancers that harbour the same BRAF(V600E) mutation are intrinsically resistant to BRAF inhibitors, due to feedback activation of the epidermal growth factor receptor (EGFR). Here we show that 6 out of 16 melanoma tumours analysed acquired EGFR expression after the development of resistance to BRAF or MEK inhibitors. Using a chromatin-regulator-focused short hairpin RNA (shRNA) library, we find that suppression of sex determining region Y-box 10 (SOX10) in melanoma causes activation of TGF-β signalling, thus leading to upregulation of EGFR and platelet-derived growth factor receptor-β (PDGFRB), which confer resistance to BRAF and MEK inhibitors. Expression of EGFR in melanoma or treatment with TGF-β results in a slow-growth phenotype with cells displaying hallmarks of oncogene-induced senescence. However, EGFR expression or exposure to TGF-β becomes beneficial for proliferation in the presence of BRAF or MEK inhibitors. In a heterogeneous population of melanoma cells having varying levels of SOX10 suppression, cells with low SOX10 and consequently high EGFR expression are rapidly enriched in the presence of drug, but this is reversed when the drug treatment is discontinued. We find evidence for SOX10 loss and/or activation of TGF-β signalling in 4 of the 6 EGFR-positive drug-resistant melanoma patient samples. Our findings provide a rationale for why some BRAF or MEK inhibitor-resistant melanoma patients may regain sensitivity to these drugs after a 'drug holiday' and identify patients with EGFR-positive melanoma as a group that may benefit from re-treatment after a drug holiday.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“However, adaptive feedback resistance has been a key limitation in prior clinical efforts to target the RAS-MAPK pathway.”
From Vertical Pathway Inhibition Overcomes Adaptive Feedback Resistance to KRASG12C Inhibition (2020) · cites this paper as [32]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“For example, RTK-driven feedback reactivation of RAS-MAPK signaling has been identified as a key driver of resistance in BRAFV600E cancers treated with BRAF inhibitors (colorectal cancer in particular) and in KRAS-mutant cancers treated with MEK inhibitors (11,12,32).”
From Vertical Pathway Inhibition Overcomes Adaptive Feedback Resistance to KRASG12C Inhibition (2020) · cites this paper as [32]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Multiple studies have demonstrated that in BRAF V600E mutant cancers, BRAF inhibition can lead to rapid EGFR-mediated feedback activation [95,96,104].”
From Emerging Insights into Targeted Therapy-Tolerant Persister Cells in Cancer (2021) · cites this paper as [104]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mutations of the BRAF gene in human cancer
Davies, H., Bignell, G. R., Cox, C., Stephens, P., Edkins, S., Clegg, S., Teague, J., Woffendin, H., Garnett, M. J., Bottomley, W., et al. (2002) · Nature · doi:10.1038/nature00766 · Cited by 10,674
Improved survival with vemurafenib in melanoma with BRAF V600E mutation
Chapman, P. B., Hauschild, A., Robert, C., Haanen, J. B., Ascierto, P., Larkin, J., Dummer, R., Garbe, C., Testori, A., Maio, M., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103782 · Cited by 7,720
Self-citationOncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a
Serrano, M., Lin, A. W., McCurrach, M. E., Beach, D., & Lowe, S. W. (1997) · Cell · doi:10.1016/s0092-8674(00)81902-9 · Cited by 5,218
Systematic identification of genomic markers of drug sensitivity in cancer cells
Garnett, M. J., Edelman, E. J., Heidorn, S. J., Greenman, C. D., Dastur, A., Lau, K. W., Greninger, P., Thompson, I. R., Luo, X., Soares, J., et al. (2012) · Nature · doi:10.1038/nature11005 · Cited by 2,456
Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation
Nazarian, R., Shi, H., Wang, Q., Kong, X., Koya, R. C., Lee, H., Chen, Z., Lee, M.-K., Attar, N., Sazegar, H., et al. (2010) · Nature · doi:10.1038/nature09626 · Cited by 2,192
Improved Survival with MEK Inhibition in BRAF-Mutated Melanoma
Flaherty, K. T., Robert, C., Hersey, P., Nathan, P., Garbe, C., Milhem, M., Demidov, L. V., Hassel, J. C., Rutkowski, P., Mohr, P., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1203421 · Cited by 2,160
Self-citationBRAFE600-associated senescence-like cell cycle arrest of human naevi
Michaloglou, C., Vredeveld, L. C. W., Soengas, M. S., Denoyelle, C., Kuilman, T., van der Horst, C. M. A. M., Majoor, D. M., Shay, J. W., Mooi, W. J., & Peeper, D. S. (2005) · Nature · doi:10.1038/nature03890 · Cited by 2,160
Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR
Prahallad, A., Sun, C., Huang, S., Di Nicolantonio, F., Salazar, R., Zecchin, D., Beijersbergen, R. L., Bardelli, A., & Bernards, R. (2012) · Nature · doi:10.1038/nature10868 · Cited by 2,051
Self-citationCOT drives resistance to RAF inhibition through MAP kinase pathway reactivation
Johannessen, C. M., Boehm, J. S., Kim, S. Y., Thomas, S. R., Wardwell, L., Johnson, L. A., Emery, C. M., Stransky, N., Cogdill, A. P., Barretina, J., et al. (2010) · Nature · doi:10.1038/nature09627 · Cited by 1,460
RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E)
Poulikakos, P. I., Persaud, Y., Janakiraman, M., Kong, X., Ng, C., Moriceau, G., Shi, H., Atefi, M., Titz, B., Gabay, M. T., et al. (2011) · Nature · doi:10.1038/nature10662 · Cited by 1,454
Cited by
Oncogenic Signaling Pathways in The Cancer Genome Atlas
Sanchez-Vega, F., Mina, M., Armenia, J., Chatila, W. K., Luna, A., La, K. C., Dimitriadoy, S., Liu, D. L., Kantheti, H. S., Saghafinia, S., et al. (2018) · Cell · doi:10.1016/j.cell.2018.03.035 · Cited by 3,201
“Since oncogenic EGFR can be synthetically lethal with mutated KRAS and can mediate resistance to BRAF inhibition in colon cancer and melanoma (Sun et al., 2014; Unni et al., 2015), these results suggest a similar antagonistic interaction with loss of NF1 or RASA1 .”
BackgroundRare cell variability and drug-induced reprogramming as a mode of cancer drug resistance
Shaffer, S. M., Dunagin, M. C., Torborg, S. R., Torre, E. A., Emert, B., Krepler, C., Beqiri, M., Sproesser, K., Brafford, P. A., Xiao, M., et al. (2017) · Nature · doi:10.1038/nature22794 · Cited by 1,218
“com/AstraZeneca-NGS/ VarDict), and Freebayes (15) algorithms.”
Targeting RAS–ERK signalling in cancer: promises and challenges
Samatar, A. A., & Poulikakos, P. I. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4281 · Cited by 1,163
Targeting TGF-β signal transduction for fibrosis and cancer therapy
Peng, D., Fu, M., Wang, M., Wei, Y., & Wei, X. (2022) · Molecular Cancer · doi:10.1186/s12943-022-01569-x · Cited by 1,065
“Both of them help increase melanoma metastatic potential and drug resistance [137, 138].”
BackgroundTargeting TGF-β Signaling in Cancer
Colak, S., & ten Dijke, P. (2017) · Trends in cancer · doi:10.1016/j.trecan.2016.11.008 · Cited by 1,003
Tsoi, J., Robert, L., Paraiso, K., Galvan, C., Sheu, K. M., Lay, J., Wong, D. J. L., Atefi, M., Shirazi, R., Wang, X., et al. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.03.017 · Cited by 938
“In some cases, dedifferentiation can be a transient response of adaptive resistance (Fallahi-Sichani et al., 2017; Sun et al., 2014; Titz et al., 2016) and provides a reservoir of cells allowing for expansion or evolution of resistant clones with genetic mechanisms that enable return to the parental differentiation st…”
BackgroundThe great escape: tumour cell plasticity in resistance to targeted therapy
Boumahdi, S., & de Sauvage, F. J. (2020) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0044-1 · Cited by 761
Evolving therapeutic landscape of advanced hepatocellular carcinoma
Yang, C., Zhang, H., Zhang, L., Zhu, A. X., Bernards, R., Qin, W., & Wang, C. (2023) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-022-00704-9 · Cited by 727
Self-citationInterrogating open issues in cancer precision medicine with patient-derived xenografts
Byrne, A. T., Alférez, D. G., Amant, F., Annibali, D., Arribas, J., Biankin, A. V., Bruna, A., Budinská, E., Caldas, C., Chang, D. K., et al. (2017) · Nature Reviews Cancer · doi:10.1038/nrc.2016.140 · Cited by 657
Low MITF/AXL ratio predicts early resistance to multiple targeted drugs in melanoma
Müller, J., Krijgsman, O., Tsoi, J., Robert, L., Hugo, W., Song, C., Kong, X., Possik, P. A., Cornelissen-Steijger, P. D. M., Foppen, M. H. G., et al. (2014) · Nature Communications · doi:10.1038/ncomms6712 · Cited by 639
Self-citationSchadendorf, D., Fisher, D. E., Garbe, C., Gershenwald, J. E., Grob, J.-J., Halpern, A., Herlyn, M., Marchetti, M. A., McArthur, G., Ribas, A., et al. (2015) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2015.3 · Cited by 613
Lahn, M., Herbertz, S., Sawyer, J. S., Stauber, A. J., Gueorguieva, I., Driscoll, K. E., Estrem, S. T., Cleverly, A. L., Desaiah, D., Guba, S. C., et al. (2015) · Drug Design, Development and Therapy · doi:10.2147/dddt.s86621 · Cited by 554
“For example, TGF-β can cause resistance to proto-oncogene B-Raf (BRAF) inhibition, and melanoma cell lines with a BRAF mutation also often have a mesenchymal phenotype.(174,175) While pSMAD2 was inhibited in PDX of melanoma, no growth inhibitory effect was observed in the same PDX using a standard tumor colony assay.”
Negative feedback regulation of the ERK1/2 MAPK pathway
Lake, D., Corrêa, S. A. L., & Müller, J. (2016) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-016-2297-8 · Cited by 565
Resistance to anti-EGFR therapy in colorectal cancer: From heterogeneity to convergent evolution
Misale, S., Di Nicolantonio, F., Sartore-Bianchi, A., Siena, S., & Bardelli, A. (2014) · Cancer Discovery · doi:10.1158/2159-8290.cd-14-0462 · Cited by 513
“A similar phenomenon has been described for BRAF mutant melanoma cells, which become resistant to vemurafenib through expression of EGFR (81).”
BackgroundSelf-citationRational combinations of targeted cancer therapies: background, advances and challenges
Jin, H., Wang, L., & Bernards, R. (2023) · Nature Reviews Drug Discovery · doi:10.1038/s41573-022-00615-z · Cited by 503
Self-citationTherapy-induced tumour secretomes promote resistance and tumour progression
Obenauf, A. C., Zou, Y., Ji, A. L., Vanharanta, S., Shu, W., Shi, H., Kong, X., Bosenberg, M. C., Wiesner, T., Rosen, N., et al. (2015) · Nature · doi:10.1038/nature14336 · Cited by 494
Vertical Pathway Inhibition Overcomes Adaptive Feedback Resistance to KRASG12C Inhibition
Ryan, M. B., Fece de la Cruz, F., Phat, S., Myers, D. T., Wong, E., Shahzade, H. A., Hong, C. B., & Corcoran, R. B. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-3523 · Cited by 496
“For example, RTK-driven feedback reactivation of RAS-MAPK signaling has been identified as a key driver of resistance in BRAF cancers treated with BRAF inhibitors (colorectal cancer in particular) and in KRAS-mutant cancers treated with MEK inhibitors (11, 12, 32).”
BackgroundDecoding the regulatory landscape of melanoma reveals TEADS as regulators of the invasive cell state
Verfaillie, A., Imrichova, H., Atak, Z. K., Dewaele, M., Rambow, F., Hulselmans, G., Christiaens, V., Svetlichnyy, D., Luciani, F., Van den Mooter, L., et al. (2015) · Nature Communications · doi:10.1038/ncomms7683 · Cited by 489
“TF TFBS Chlp TFBS Chlp TFBS Chlp MITF/501Mel 1 (1) 31.”
BackgroundTargeting cancer with kinase inhibitors
Gross, S., Rahal, R., Stransky, N., Lengauer, C., & Hoeflich, K. P. (2015) · Journal of Clinical Investigation · doi:10.1172/jci76094 · Cited by 444
EGFR activation limits the response of liver cancer to lenvatinib
Jin, H., Shi, Y., Lv, Y., Yuan, S., Ramirez, C. F. A., Lieftink, C., Wang, L., Wang, S., Wang, C., Dias, M. H., et al. (2021) · Nature · doi:10.1038/s41586-021-03741-7 · Cited by 440
Self-citationcisTopic: cis-regulatory topic modeling on single-cell ATAC-seq data
Bravo González-Blas, C., Minnoye, L., Papasokrati, D., Aibar, S., Hulselmans, G., Christiaens, V., Davie, K., Wouters, J., & Aerts, S. (2019) · Nature Methods · doi:10.1038/s41592-019-0367-1 · Cited by 456
YAP/TAZ Signaling and Resistance to Cancer Therapy
Nguyen, C. D. K., & Yi, C. (2019) · Trends in Cancer · doi:10.1016/j.trecan.2019.02.010 · Cited by 437
Cell-cell communication: New insights and clinical implications
Su, J., Song, Y., Zhu, Z., Huang, X., Fan, J., Qiao, J., & Mao, F. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01888-z · Cited by 433
Signal pathways of melanoma and targeted therapy
Guo, W., Wang, H., & Li, C. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00827-6 · Cited by 379
“In a previous study on the mechanism underlying vemurafenib resistance, using a chromatin-regulator-focused shRNA library, the authors identified the loss of SOX10 expression as a crucial cause of the resistance to targeted therapy via the activation of transforming growth factor-β (TGF-β) signaling and subsequent upr…”
BackgroundCombine and conquer: challenges for targeted therapy combinations in early phase trials
Lopez, J. S., & Banerji, U. (2017) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.96 · Cited by 394
“While a drug holiday can on occasion enable patients to regain sensitivity to the same drug, this is usually due to reversal of compensatory feedback loops and expansion of sensitive tumours clones.[82, 83] Another example is the lack of single-agent activity of MEK inhibitors in multiple”
BackgroundPhenotype plasticity as enabler of melanoma progression and therapy resistance
Arozarena, I., & Wellbrock, C. (2019) · Nature Reviews Cancer · doi:10.1038/s41568-019-0154-4 · Cited by 381
Long, G. V., Fung, C., Menzies, A. M., Pupo, G. M., Carlino, M. S., Hyman, J., Shahheydari, H., Tembe, V., Thompson, J. F., Saw, R. P., et al. (2014) · Nature Communications · doi:10.1038/ncomms6694 · Cited by 375
The dynamic control of signal transduction networks in cancer cells
Kolch, W., Halasz, M., Granovskaya, M., & Kholodenko, B. N. (2015) · Nature Reviews Cancer · doi:10.1038/nrc3983 · Cited by 339
Independent Drug Action in Combination Therapy: Implications for Precision Oncology
Plana, D., Palmer, A. C., & Sorger, P. K. (2022) · Cancer Discovery · doi:10.1158/2159-8290.cd-21-0212 · Cited by 307
An Acquired Vulnerability of Drug-Resistant Melanoma with Therapeutic Potential
Wang, L., Leite de Oliveira, R., Huijberts, S., Bosdriesz, E., Pencheva, N., Brunen, D., Bosma, A., Song, J.-Y., Zevenhoven, J., Los-de Vries, G. T., et al. (2018) · Cell · doi:10.1016/j.cell.2018.04.012 · Cited by 327
“HDACi Confers a Disadvantage to MAPKi-Resistant Melanoma We have shown previously that acquisition of resistance to vemurafenib leads to a transient proliferation arrest upon drugwithdrawal, phenocopying the transient arrest in tumor growth upon drug withdrawal seen in the clinic, known as the drug holiday effect (Seg…”
InfluentialSelf-citationLee, J. H., Shklovskaya, E., Lim, S. Y., Carlino, M. S., Menzies, A. M., Stewart, A., Pedersen, B., Irvine, M., Alavi, S., Yang, J. Y. H., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-15726-7 · Cited by 288
“Age, median (range) 67 (38–88) Sex, n (%) Male 38 (56) Female 30 (44) Prior BRAF±MEK inhibitor therapy Yes 23 (34) No 45 (66) M Stage (AJCC 8th edition), n (%) M1a 6 (9) M1b 8 (12) M1c 38 (56) M1d 16 (23) Mutationa, n (%) BRAFV600 19 (28) NRAS 16 (24) Otherb/none 33 (48) LDH at baseline, n (%) ≤ULN 40 (59) >ULN 28 (41…”
Pisco, A. O., & Huang, S. (2015) · British Journal of Cancer · doi:10.1038/bjc.2015.146 · Cited by 283
“MOST STUDIES DO NOT DISTINGUISH BETWEEN DARWINIAN AND LAMARCKIAN SCHEME IN RESISTANCE DEVELOPMENT Often in the literature terms such as ‘acquisition’, ‘enrichment’ or ‘induction’ of stemness and resistance (Pardoll, 2012; Heams et al, 2014; Sun et al, 2014), as well as expressions such as ‘activation of alternative pa…”
BackgroundInfluentialSelf-citationDynamics-Driven Allostery in Protein Kinases
Kornev, A. P., & Taylor, S. S. (2015) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2015.09.002 · Cited by 284
“Although the V600E mutation is the most common mutation associated with melanoma[56], V600F also stabilizes the C-helix and leads to constitutive activation of BRAF[39] indicating once again the importance of hydrophobic substitutions that can shift the balance between active and inactive states and hijack a complex r…”
BackgroundRobust gene expression programs underlie recurrent cell states and phenotype switching in melanoma
Wouters, J., Kalender-Atak, Z., Minnoye, L., Spanier, K. I., De Waegeneer, M., Bravo González-Blas, C., Mauduit, D., Davie, K., Hulselmans, G., Najem, A., et al. (2020) · Nature Cell Biology · doi:10.1038/s41556-020-0547-3 · Cited by 258
Stuhlmiller, T. J., Miller, S. M., Zawistowski, J. S., Nakamura, K., Beltran, A. S., Duncan, J. S., Angus, S. P., Collins, K. A. L., Granger, D. A., Reuther, R. A., et al. (2015) · Cell Reports · doi:10.1016/j.celrep.2015.03.037 · Cited by 270
Resistant mechanisms to BRAF inhibitors in melanoma
Manzano, J. L., Layos, L., Bugés, C., de los Llanos Gil, M., Vila, L., Martínez-Balibrea, E., & Martínez-Cardús, A. (2016) · Annals of Translational Medicine · doi:10.21037/atm.2016.06.07 · Cited by 255
“In this case, it is possible restoring sensitivity by inhibiting EGFR (40).”
BackgroundInfluentialActin remodeling confers BRAF inhibitor resistance to melanoma cells through YAP / TAZ activation
Kim, M. H., Kim, J., Hong, H., Lee, S., Lee, J., Jung, E., & Kim, J. (2016) · The EMBO Journal · doi:10.15252/embj.201592081 · Cited by 265
“Several studies have identified potential mechanisms of BRAF inhibitor resistance: EGFR upregulation driven by SOX10 loss (Girotti et al , 2013; Sun et al , 2014), acquired NRAS and MEK1 mutations (Van Allen et al , 2014), WNT5A upregulation (Anastas et al , 2014), and BRAF alternative splicing…”
Tumor cell plasticity in targeted therapy-induced resistance: Mechanisms and new strategies
Shi, Z.-D., Pang, K., Wu, Z.-X., Dong, Y., Hao, L., Qin, J.-X., Wang, W., Chen, Z.-S., & Han, C.-H. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01383-x · Cited by 256
“ID3 acted as a transcriptional repressor of sex-determining region Y-box 10 (SOX10) and MITF, thereby promoting tumor cell transformation to a drug-resistant phenotype.122 Moreover, Sun et al.123 also observed an increase in the percentage of SOX10low EGFRhigh melanoma cells after BRAFi and MEKi treatment.”
BackgroundSmith, M. P., Brunton, H., Rowling, E. J., Ferguson, J., Arozarena, I., Miskolczi, Z., Lee, J. L., Girotti, M. R., Marais, R., Levesque, M. P., et al. (2016) · Cancer Cell · doi:10.1016/j.ccell.2016.02.003 · Cited by 246
“Selection for sub-populations might also occur as seen with epidermal growth factor receptor (EGFR)-expressing cells (Sun et al., 2014).”
BackgroundRiesenberg, S., Groetchen, A., Siddaway, R., Bald, T., Reinhardt, J., Smorra, D., Kohlmeyer, J., Renn, M., Phung, B., Aymans, P., et al. (2015) · Nature Communications · doi:10.1038/ncomms9755 · Cited by 227
Feedback Activation of STAT3 as a Cancer Drug-Resistance Mechanism
Zhao, C., Li, H., Lin, H.-J., Yang, S., Lin, J., & Liang, G. (2016) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2015.10.001 · Cited by 237
“Numerous studies have reported that activation of hepatocyte growth factor receptor (MET proto-oncogene, receptor tyrosine kinase), insulin-like growth factor type 1 receptor (IGF-1R), epidermal growth factor receptor (EGFR), nuclear transcription factor kB (NF-kB), and fibroblast growth factor receptor (FGFR) is part…”
BackgroundFallahi‐Sichani, M., Becker, V., Izar, B., Baker, G. J., Lin, J., Boswell, S. A., Shah, P., Rotem, A., Garraway, L. A., & Sorger, P. K. (2017) · Molecular Systems Biology · doi:10.15252/msb.20166796 · Cited by 235
Wellbrock, C., & Arozarena, I. (2015) · Pigment Cell & Melanoma Research · doi:10.1111/pcmr.12370 · Cited by 217
“Strikingly, two other crucial MITF regulators FOXD3 and SOX10 are also found upregulated in response to MAPK pathway inhibition (Abel et al., 2013; Sun et al., 2014).”
Su, Y., Wei, W., Robert, L., Xue, M., Tsoi, J., Garcia-Diaz, A., Homet Moreno, B., Kim, J., Ng, R. H., Lee, J. W., et al. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1712064115 · Cited by 228
“For some patient-derived cell lines, these drug-induced cell state transitions are reversed on drug release (5, 6).”
BackgroundMethodWang, L., Leite de Oliveira, R., Wang, C., Fernandes Neto, J. M., Mainardi, S., Evers, B., Lieftink, C., Morris, B., Jochems, F., Willemsen, L., et al. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.09.085 · Cited by 224
Self-citationDrug resistance to targeted therapies: Déjà vu all over again
Groenendijk, F. H., & Bernards, R. (2014) · Molecular Oncology · doi:10.1016/j.molonc.2014.05.004 · Cited by 209
Self-citationTargeted Therapy in Melanoma and Mechanisms of Resistance
Czarnecka, A. M., Bartnik, E., Fiedorowicz, M., & Rutkowski, P. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21134576 · Cited by 196
“A decrease in the activity of sex determining region Y-box 10 (SOX10) described in some melanomas may lead to signalization through TGF-β, which in turn leads to an increase in the expression of EGFR and the receptor of the platelet-derived growth factor (PDGFRB) [5,73].”
BackgroundIdentifying chemogenetic interactions from CRISPR screens with drugZ
Colic, M., Wang, G., Zimmermann, M., Mascall, K., McLaughlin, M., Bertolet, L., Lenoir, W. F., Moffat, J., Angers, S., Durocher, D., et al. (2019) · Genome Medicine · doi:10.1186/s13073-019-0665-3 · Cited by 219
“Neither hit is reported in the original study, but both MCL1 [50] and EGFR [51, 52] have been characterized as routes of adaptive resistance to BRAF inhibition in melanoma.”
BackgroundBRAF Mutations in Melanoma: Biological Aspects, Therapeutic Implications, and Circulating Biomarkers
Castellani, G., Buccarelli, M., Arasi, M. B., Rossi, S., Pisanu, M. E., Bellenghi, M., Lintas, C., & Tabolacci, C. (2023) · Cancers · doi:10.3390/cancers15164026 · Cited by 186
“The switch between distinct transcriptional programs driving the cellular plasticity of melanoma cells has been widely described as a mechanism of targeted therapy resistance [126,127].”
BackgroundTGF-β Signaling and Resistance to Cancer Therapy
Zhang, M., Zhang, Y. Y., Chen, Y., Wang, J., Wang, Q., & Lu, H. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.786728 · Cited by 191
“A number of recent studies have shown that activation of transforming growth factor β (TGF-β) signaling was associated with drug resistance in a variety of cancers including melanoma (Sun et al., 2014), NSCLC (Soucheray et al.”
BackgroundInfluentialAcquired and intrinsic resistance in cancer immunotherapy
Kelderman, S., Schumacher, T. N. M., & Haanen, J. B. A. G. (2014) · Molecular Oncology · doi:10.1016/j.molonc.2014.07.011 · Cited by 197
Self-citationTumor Evolution as a Therapeutic Target
Amirouchene-Angelozzi, N., Swanton, C., & Bardelli, A. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-0343 · Cited by 194
Self-citationPrecision Oncology: The Road Ahead
Senft, D., Leiserson, M. D. M., Ruppin, E., & Ronai, Z. A. (2017) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2017.08.003 · Cited by 195
Schreuer, M., Jansen, Y., Planken, S., Chevolet, I., Seremet, T., Kruse, V., & Neyns, B. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30171-7 · Cited by 184
Lee, H. W., Chung, W., Lee, H.-O., Jeong, D. E., Jo, A., Lim, J. E., Hong, J. H., Nam, D.-H., Jeong, B. C., Park, S. H., et al. (2020) · Genome Medicine · doi:10.1186/s13073-020-00741-6 · Cited by 183
Principles and mechanisms of non-genetic resistance in cancer
Bell, C. C., & Gilan, O. (2020) · British Journal of Cancer · doi:10.1038/s41416-019-0648-6 · Cited by 182
Emerging Insights into Targeted Therapy-Tolerant Persister Cells in Cancer
Cabanos, H. F., & Hata, A. N. (2021) · Cancers · doi:10.3390/cancers13112666 · Cited by 189
Current Advances in the Treatment of BRAF-Mutant Melanoma
Patel, H., Yacoub, N., Mishra, R., White, A., Yuan, L., Alanazi, S., & Garrett, J. T. (2020) · Cancers · doi:10.3390/cancers12020482 · Cited by 174
“Starting from the cell surface, several receptor tyrosine kinases (RTK) converge onto parallel pathways such as the MAPK and the PI3K-Akt pathway [39].”
BackgroundAutophagy inhibition overcomes multiple mechanisms of resistance to BRAF inhibition in brain tumors
Mulcahy Levy, J. M., Zahedi, S., Griesinger, A. M., Morin, A., Davies, K. D., Aisner, D. L., Kleinschmidt-DeMasters, B., Fitzwalter, B. E., Goodall, M. L., Thorburn, J., et al. (2017) · eLife · doi:10.7554/elife.19671 · Cited by 175
“inhibition quickly develop resistance to therapy (Hartsough et al., 2014; Sun et al., 2014).”
BackgroundInfluentialAn approach to suppress the evolution of resistance in BRAFV600E-mutant cancer
Xue, Y., Martelotto, L., Baslan, T., Vides, A., Solomon, M., Mai, T. T., Chaudhary, N., Riely, G. J., Li, B. T., Scott, K., et al. (2017) · Nature Medicine · doi:10.1038/nm.4369 · Cited by 174
Li, S., Song, Y., Quach, C., Guo, H., Jang, G.-B., Maazi, H., Zhao, S., Sands, N. A., Liu, Q., In, G. K., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-09634-8 · Cited by 165
Advances in CRISPR-Cas9 genome engineering: lessons learned from RNA interference
Barrangou, R., Birmingham, A., Wiemann, S., Beijersbergen, R. L., Hornung, V., & Smith, A. V. B. (2015) · Nucleic Acids Research · doi:10.1093/nar/gkv226 · Cited by 165
“An example of such a gene is SOX10, which causes a slow-growth phenotype upon knockdown; this phenotype is associated with resistance to vemurafenib (95).”
BackgroundSelf-citationSomatic driver mutations in melanoma
Reddy, B. Y., Miller, D. M., & Tsao, H. (2017) · Cancer · doi:10.1002/cncr.30593 · Cited by 160
“Studies have demonstrated that EGFR inhibition leads to the restoration of sensitivity, indicating a possible future clinical strategy.(36) The current gold standard of targeted therapy in BRAF-mutant metastatic melanoma is a combination of BRAFi and MEK inhibitor (MEKi).”
BackgroundMechanisms and strategies to overcome resistance to molecularly targeted therapy for melanoma
Lim, S. Y., Menzies, A. M., & Rizos, H. (2017) · Cancer · doi:10.1002/cncr.30435 · Cited by 162
“growth factor receptor expression in more than 30% of BRAF- and MEK-resistant tumors.(83) In addition to mela-”
BackgroundPTPN11 is a central node in intrinsic and acquired resistance to targeted cancer drugs
Prahallad, A., Heynen, G. J. J. E., Germano, G., Willems, S. M., Evers, B., Vecchione, L., Gambino, V., Lieftink, C., Beijersbergen, R. L., Di Nicolantonio, F., et al. (2015) · Cell Reports · doi:10.1016/j.celrep.2015.08.037 · Cited by 168
“Especially the latter two mechanisms often involve activation of RTKs that fuel reactivation of the inhibited pathway (Duncan et al., 2012; Sun et al., 2014b; Nazarian et al., 2010).”
InfluentialSelf-citationBRAF-mutant melanoma: treatment approaches, resistance mechanisms, and diagnostic strategies
Spagnolo, F., Ghiorzo, P., Orgiano, L., Pastorino, L., Picasso, V., Tornari, E., Ottaviano, V., & Queirolo, P. (2015) · OncoTargets and Therapy · doi:10.2147/ott.s39096 · Cited by 160
Variability within rare cell states enables multiple paths toward drug resistance
Emert, B. L., Cote, C. J., Torre, E. A., Dardani, I. P., Jiang, C. L., Jain, N., Shaffer, S. M., & Raj, A. (2021) · Nature Biotechnology · doi:10.1038/s41587-021-00837-3 · Cited by 164
miR-204-5p and miR-211-5p Contribute to BRAF Inhibitor Resistance in Melanoma
Díaz‐Martínez, M., Benito-Jardón, L., Alonso, L., Koetz‐Ploch, L., Hernando, E., & Teixidó, J. (2017) · Cancer Research · doi:10.1158/0008-5472.can-17-1318 · Cited by 172
CD44 Promotes PD-L1 Expression and Its Tumor-Intrinsic Function in Breast and Lung Cancers
Kong, T., Ahn, R., Yang, K., Zhu, X., Fu, Z., Morin, G., Bramley, R., Cliffe, N. C., Xue, Y., Kuasne, H., et al. (2019) · Cancer Research · doi:10.1158/0008-5472.can-19-1108 · Cited by 175
“Genomic DNAwas isolated and shRNA inserts were recovered with PCR amplification performed as described (32).”
MethodSelf-citationvan Staalduinen, J., Baker, D., ten Dijke, P., & van Dam, H. (2018) · Oncogene · doi:10.1038/s41388-018-0378-x · Cited by 158
Feedback and redundancy in receptor tyrosine kinase signaling: relevance to cancer therapies
Sun, C., & Bernards, R. (2014) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2014.08.010 · Cited by 155
Self-citationCancer drug addiction is relayed by an ERK2-dependent phenotype switch
Kong, X., Kuilman, T., Shahrabi, A., Boshuizen, J., Kemper, K., Song, J.-Y., Niessen, H. W. M., Rozeman, E. A., Geukes Foppen, M. H., Blank, C. U., et al. (2017) · Nature · doi:10.1038/nature24037 · Cited by 153
Self-citationDevelopmental chromatin programs determine oncogenic competence in melanoma
Baggiolini, A., Callahan, S. J., Montal, E., Weiss, J. M., Trieu, T., Tagore, M. M., Tischfield, S. E., Walsh, R. M., Suresh, S., Fan, Y., et al. (2021) · Science · doi:10.1126/science.abc1048 · Cited by 158
“Recent work has demonstrated that up-regulation of EGFR and FGF, which we found is facilitated by ATAD2, are key mechanisms of MAPK pathway activation in BRAF mutant melanoma, especially in the setting of drug resistance (25, 26).”
Ahmed, F., & Haass, N. K. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00173 · Cited by 161
Mechanisms of Acquired BRAF Inhibitor Resistance in Melanoma: A Systematic Review
Proietti, I., Skroza, N., Bernardini, N., Tolino, E., Balduzzi, V., Marchesiello, A., Michelini, S., Volpe, S., Mambrin, A., Mangino, G., et al. (2020) · Cancers · doi:10.3390/cancers12102801 · Cited by 145
“STAT3 [28,122,131,139] miR-7 [59] FLI1 [121] miR-92a-15p [150,152] RUNX [123,129] miR-204-5p [147,149] YAP [14,22,45] miR-211-5p [147] c-MYC [138] miR-126-3p [146] Aryl hyodrocarbon receptor [125] miR-514a [154] SOX proteins (SOX2, SOX10) [58,126,130,131] miR-579-3p [148] β-catenin [120,124,139] miR-4443 [149] MITF [4…”
Orgaz, J. L., Crosas-Molist, E., Sadok, A., Perdrix-Rosell, A., Maiques, O., Rodriguez-Hernandez, I., Monger, J., Mele, S., Georgouli, M., Bridgeman, V., et al. (2020) · Cancer Cell · doi:10.1016/j.ccell.2019.12.003 · Cited by 151
“A common event during melanoma resistance is BRAFi/MEKi addiction, which occurs when resistant melanomas become drug dependent (Das Thakur et al., 2013; Hong et al., 2017; Kong et al., 2017; Moriceau et al., 2015; Sun et al., 2014).”
BackgroundResultInfluentialMechanisms of resistance to EZH2 inhibitors in diffuse large B-cell lymphomas
Bisserier, M., & Wajapeyee, N. (2018) · Blood · doi:10.1182/blood-2017-08-804344 · Cited by 160
Surviving apoptosis: life–death signaling in single cells
Flusberg, D. A., & Sorger, P. K. (2015) · Trends in Cell Biology · doi:10.1016/j.tcb.2015.03.003 · Cited by 149
The nuclear translocation of ERK1/2 as an anticancer target
Plotnikov, A., Flores, K., Maik-Rachline, G., Zehorai, E., Kapri-Pardes, E., Berti, D. A., Hanoch, T., Besser, M. J., & Seger, R. (2015) · Nature Communications · doi:10.1038/ncomms7685 · Cited by 142
Clonal fitness inferred from time-series modelling of single-cell cancer genomes
Salehi, S., Kabeer, F., Ceglia, N., Andronescu, M., Williams, M. J., Campbell, K. R., Masud, T., Wang, B., Biele, J., Brimhall, J., et al. (2021) · Nature · doi:10.1038/s41586-021-03648-3 · Cited by 152
Ramsdale, R., Jorissen, R. N., Li, F. Z., Al-Obaidi, S., Ward, T., Sheppard, K. E., Bukczynska, P. E., Young, R. J., Boyle, S. E., Shackleton, M., et al. (2015) · Science Signaling · doi:10.1126/scisignal.aab1111 · Cited by 143
Kemper, K., Krijgsman, O., Cornelissen‐Steijger, P., Shahrabi, A., Weeber, F., Song, J., Kuilman, T., Vis, D. J., Wessels, L. F., Voest, E. E., et al. (2015) · EMBO Molecular Medicine · doi:10.15252/emmm.201404914 · Cited by 140
“Previously, it has been shown that hyperactivation of the MAPK pathway can diminish cell proliferation and survival (Sun et al , 2014; Moriceau et al , 2015).”
Self-citationCell death-based treatments of melanoma:conventional treatments and new therapeutic strategies
Mattia, G., Puglisi, R., Ascione, B., Malorni, W., Carè, A., & Matarrese, P. (2018) · Cell Death and Disease · doi:10.1038/s41419-017-0059-7 · Cited by 151
Epithelial‐to‐mesenchymal‐like transition events in melanoma
Pedri, D., Karras, P., Landeloos, E., Marine, J., & Rambow, F. (2022) · The FEBS Journal · doi:10.1111/febs.16021 · Cited by 126
He, J., Qiu, Z., Fan, J., Xie, X., Sheng, Q., & Sui, X. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01891-4 · Cited by 160
“174 It is noteworthy that targeting multiple sites along the EGFR signaling pathway and its downstream pathways, through the combined use of a BRAF inhibitor and an EGFR inhibitor, has shown greater ef fi cacy in treating drug-resistant BRAF (V600E) colon cancer patients.”
BackgroundThe Complexity of the ERK/MAP-Kinase Pathway and the Treatment of Melanoma Skin Cancer
Wellbrock, C., & Arozarena, I. (2016) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2016.00033 · Cited by 145
Adolescent and young adult patients with cancer: a milieu of unique features
Sender, L., & Zabokrtsky, K. B. (2015) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2015.92 · Cited by 130
Conditional Selection of Genomic Alterations Dictates Cancer Evolution and Oncogenic Dependencies
Mina, M., Raynaud, F., Tavernari, D., Battistello, E., Sungalee, S., Saghafinia, S., Laessle, T., Sanchez-Vega, F., Schultz, N., Oricchio, E., et al. (2017) · Cancer Cell · doi:10.1016/j.ccell.2017.06.010 · Cited by 129
“In light of recent reports of synthetic lethal interactions between EGFR and KRAS or BRAF mutations (Sun et al., 2014; Unni et al., 2015), our results suggest that this phenomenon could be associated with a broad group of MAPK regulators and RTKs that are altered in large and heterogeneous patient populations.”
BackgroundInfluentialOvercoming resistance to BRAF inhibition in BRAF-mutated metastatic melanoma
Spagnolo, F., Ghiorzo, P., & Queirolo, P. (2014) · Oncotarget · doi:10.18632/oncotarget.2602 · Cited by 139
“Many RTKs share the RASMEK-ERK and the PI3K-AKT signaling pathways: consistent with this, dual inhibition of the two pathways could restore sensitivity to BRAFi in cells with high EGFR expression [36,37].”
BackgroundResultMolecular Pathways: AXL, a Membrane Receptor Mediator of Resistance to Therapy
Scaltriti, M., Elkabets, M., & Baselga, J. M. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-1458 · Cited by 130
“In breast cancer, for example, HER3 is often overexpressed as a result of PI3K/AKT inhibition (42–44), whereas increased expression and activity of EGFR plays a pivotal role in limiting the efficacy of BRAF inhibition in colon cancer (45, 46).”
BackgroundRoesch, A. (2014) · Oncogene · doi:10.1038/onc.2014.249 · Cited by 139
The Paradoxical Role of Cellular Senescence in Cancer
Yang, J., Liu, M., Hong, D., Zeng, M., & Zhang, X. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.722205 · Cited by 114
ERK Mutations Confer Resistance to Mitogen-Activated Protein Kinase Pathway Inhibitors
Goetz, E. M., Ghandi, M., Treacy, D. J., Wagle, N., & Garraway, L. A. (2014) · Cancer Research · doi:10.1158/0008-5472.can-14-2073 · Cited by 115
“This has also been termed the “drug holiday” effect (33).”
BackgroundOddo, D., Sennott, E. M., Barault, L., Valtorta, E., Arena, S., Cassingena, A., Filiciotto, G., Marzolla, G., Elez, E., van Geel, R. M. J. M., et al. (2016) · Cancer Research · doi:10.1158/0008-5472.can-16-0396 · Cited by 121
“This result is consistent with previous observations that induction of EGFR protein expression can drive resistance to BRAFi or MEKi in melanoma (35).”
Self-citationThe Contribution of Evolutionary Game Theory to Understanding and Treating Cancer
Wölfl, B., Rietmole, H. T., Salvioli, M., Kaznatcheev, A., Thuijsman, F., Brown, J. S., Burgering, B. M. T., & Staňková, K. (2021) · Dynamic Games and Applications · doi:10.1007/s13235-021-00397-w · Cited by 139
“stalled (drug holiday), resistant types are typically at a disadvantage (cost of resistance [168], although this is not universal [113]).”
BackgroundCo-clinical assessment identifies patterns of BRAF inhibitor resistance in melanoma
Kwong, L. N., Boland, G. M., Frederick, D. T., Helms, T. L., Akid, A. T., Miller, J. P., Jiang, S., Cooper, Z. A., Song, X., Seth, S., et al. (2015) · Journal of Clinical Investigation · doi:10.1172/jci78954 · Cited by 128
“These results are consistent with those of a recent study showing that human samples overexpressing EGFR and other RTKs possess a slow-growing resistance phenotype (31), similar to that of the RTK cluster’s relatively low levels of prolifercomparable to that of the positive control RAF1, which encodes for CRAF.”
BRAF inhibitors: resistance and the promise of combination treatments for melanoma
Griffin, M., Scotto, D., Josephs, D. H., Mele, S., Crescioli, S., Bax, H. J., Pellizzari, G., Wynne, M. D., Nakamura, M., Hoffmann, R. M., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.19836 · Cited by 130
“This is reversed with BRAF or MEK inhibition, allowing low-expressing SOX10 tumor cells to be enriched in response to treatment [47].”
BackgroundDevelopmental pathways activated in melanocytes and melanoma
Liu, J., Fukunaga‐Kalabis, M., Li, L., & Herlyn, M. (2014) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2014.07.023 · Cited by 140
Jolly, M. K., Kulkarni, P., Weninger, K., Orban, J. P., & Levine, H. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00050 · Cited by 126
“In the EGFR-addicted NSCLC cell line PC9 that initially revealed the existence of DTPs upon EGFR tyrosine kinase inhibition (45), 17 different persisterderived erlotinib-resistant colonies (PERCs) were established from a single persister (87).”
BackgroundInfluentialAXL/AKT axis mediated-resistance to BRAF inhibitor depends on PTEN status in melanoma
Zuo, Q., Liu, J., Huang, L., Qin, Y., Hawley, T., Seo, C., Merlino, G., & Yu, Y. (2018) · Oncogene · doi:10.1038/s41388-018-0205-4 · Cited by 111
Metadata
- Authors
- Sun, C., Wang, L., Huang, S., Heynen, G. J. J. E., Prahallad, A., Robert, C., Haanen, J., Blank, C., Wesseling, J., Willems, S. M., Zecchin, D., Hobor, S., Bajpe, P. K., Lieftink, C., Mateus, C., Vagner, S., Grernrum, W., Hofland, I., Schlicker, A., Wessels, L. F. A., Beijersbergen, R. L., Bardelli, A., Di Nicolantonio, F., Eggermont, A. M. M., & Bernards, R.
- Affiliations
- The Netherlands Cancer Institute (NL)
- Institut Gustave Roussy (FR)
- Candiolo Cancer Institute (IT)
- IFOM (IT)
- ORCID
- Sun, Chong
- Wang, Liqin
- Huang, Sidong
- Heynen, Guus J. J. E.
- Prahallad, Anirudh
- Robert, Caroline
- Haanen, John
- Blank, Christian
- Wesseling, Jelle
- Willems, Stefan M.
- Zecchin, Davide
- Lieftink, Cor
- Hofland, Ingrid
- Schlicker, Andreas
- Wessels, Lodewyk F. A.
- Beijersbergen, Roderick L.
- Bardelli, Alberto
- Eggermont, Alexander M. M.
- Venue
- Nature
- Published
- 2014-03-26
- Volume
- 508
- Issue
- 7494
- Pages
- 118-122
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W1985928174
- Cited by
- 888
- References
- 30
- Citations by year
- 2026: 29 · 2025: 43 · 2024: 62 · 2023: 58 · 2022: 90 · 2021: 81 · 2020: 71 · 2019: 76 · 2018: 75 · 2017: 83 · 2016: 71 · 2015: 107 · 2014: 39
- FWCI
- 40.97
- Type
- journal article
- Language
- en
- Open access
- green
- hdl.handle.net
- Licence
- other-oa
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- Institutional Research Information System University of Turin (University of Turin) (submittedVersion, other-oa)
- RePEc: Research Papers in Economics (submittedVersion)
- University of Groningen research database (University of Groningen / Centre for Information Technology) (submittedVersion)
- Funders
- Canadian Institutes of Health Research (MOP130540)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Melanoma and MAPK Pathways
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Keywords
- BRAF inhibitor resistance, SOX10, TGF-beta signaling, PDGFRβ, oncogene-induced senescence, drug holidays, MEK inhibitors, adaptive resistance, shRNA screen, cell proliferation, tumor heterogeneity, drug re-sensitization, receptor tyrosine kinase
- MeSH terms
- Vemurafenib, Animals, Antineoplastic Agents, Female, Flow Cytometry, Humans, Indoles, Melanoma, Sulfonamides, Signal Transduction, Gene Library, Gene Expression Regulation, Neoplastic, Transforming Growth Factor beta, Cellular Senescence, Drug Resistance, Neoplasm, Receptor Protein-Tyrosine Kinases, Receptor, Platelet-Derived Growth Factor beta, Mitogen-Activated Protein Kinase Kinases, RNA, Small Interfering, Protein Kinase Inhibitors, Proto-Oncogene Proteins B-raf, Cell Proliferation, Mice, SOXE Transcription Factors, ErbB Receptors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.